SWECARNET - Sweden´s CAR T-cell Competence Network

Purpose and goal:

SWECARNET is an open network of key representatives in the Swedish CAR T field from academia, healthcare, and industry working towards knowledge exchange and development of standardized processes for CAR T delivery and follow-up. SWECARNET’s central goal is to implement gene-modified immune effector cell therapy, such as CAR T, so that patients in need, and likely to benefit, get access to new treatments through clinical trials or as standard of care treatment independent of where they are living in the country.

Expected results and effects:

The collaboration in this network will facilitate the translation of advanced therapies into clinical use and create an arena for innovation within academia and healthcare to be generated in, and with help from industry to reach patients. SWECARNET is expected to be at the forefront of the field both nationally and internationally and serve as a workhorse for solving challenges around the implementation of advanced therapies.

SWECARNET will act as a catalyst to increase the number of clinical trials for CAR T and other advanced therapy medicinal products in Sweden. Approach and implementation:

All members in SWECARNET will be involved and work together on 8 different work packages with an assigned project leader. SWECARNET arranges quarterly meetings where we work together, follow up and report the progress made in the various work packages. SWECARNET is led by Professor Stephan Mielke, Karolinska Institutet and Karolinska Universitetssjukhuset together with Professor Gunilla Enblad, Uppsala Universitet and Akademiska Sjukhuset.